Published in Oncology Business Week, November 1st, 2009
"Some medications compromise CYP2D6 activity and may lower plasma concentrations of active tamoxifen metabolites. We studied the association between concurrent use of tamoxifen and CYP2D6-inhibiting medications and breast cancer recurrence among Danish women diagnosed with early-stage, estrogen receptor-positive breast cancer. Using the Danish Breast Cancer Cooperative Group Registry, we identified 366 cases with local or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week